Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.

Lancet Neurol · 2020 · PMC7029307 · PMID 31981516

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a small placebo-controlled study, patients with relapsing multiple sclerosis treated with fluoxetine showed a trend towards a reduction in the number of new enhancing lesions over time.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.